Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients

Bibliography

• PARKIN DM, BRAY F, FERLAY J, PISANI P: Estimating the world cancer burden: Globocan 2000. Int. J. Cancer (2001) 94:153–156.
   PubMed Web of Science ®Google Scholar
• COLEMAN MP, GATTA G, VERDECCHIA A et al: EUROCARE-3 summary: cancer survival in Europe at the end of 20th century. Ann. Once]. (2003) 14\(Suppl. 5):128–149.
   Google Scholar
• BORRAS JM, FERNANDEZ E, GONZALEZ JR et al: Lung cancer mortality in European regions (1955-1997). Ann. Once]. (2003) 14:159–161.
   PubMed Web of Science ®Google Scholar
• TYCZYNSKI JE, BRAY F, PARKIN DM: Lung cancer in Europe in 2000: epidemiology, prevention, and early detection. Lancet Once]. (2003) 4:45–55.
   PubMed Web of Science ®Google Scholar
• JEMAL A, MURRAY T, SAMUELS A, GHAFOOR A, WARD E, THUN MJ: Cancer statistics, 2003. CA. Cancerj Clin. (2003) 53:5–26.
   PubMed Web of Science ®Google Scholar
• SILVERBERG E, LUBERA JA: Cancer statistics. CA. Cancer (1988) 38:5–22.
   PubMed Web of Science ®Google Scholar
• GRIDELLI C, PERRONE F, MONFARDINI S: Lung cancer in the elderly. Eur. J. Cancer (1997) 33:2313–2314.
   PubMed Web of Science ®Google Scholar
• HAVLIK RJ, YANCIK R, LONG S, RIES L, EDWARDS B: The National Cancer Institute on Aging and the National Cancer Institute SEER. Collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer (1994) 74\(Suppl. 7):2101–2106.
   Google Scholar
• NON-SMALL CELL LUNG CANCER COLLABORATIVE GROUP: Chemotherapy in non small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med. J. (1995) 311:899–909.
   PubMed Web of Science ®Google Scholar
• ••First meta-analysis performed about chemotherapy of NSCLC.
   Google Scholar
• JANSSEN-HEIJNEN MLG, SCHIPPER RIVI, RAZENBERG PPA, CROMMELIN MA, COEBERG JW: Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer (1998) 21:105–113.
   PubMed Web of Science ®Google Scholar
• EARLE CC, VENDITTI LN, NEUMANN PJ et al.: Who gets chemotherapy for metastatic lung cancer? Chest (2000) 117:1239–1246.
   Google Scholar
• RABY B, PATER J, MACKILLOP W: Does knowledge guide practice? Another look at the management of non-small-cell lung cancer. J. Clin. Once]. (1995) 13:1904–1911.
   PubMed Web of Science ®Google Scholar
• CROOK A, DUFFY A, GIRLING DJ, SOUHAMI RL, PARMAR MK: Survey on the treatment of non-small cell lung cancer (NSCLC) in England and Wales. Eur. Respir: J. (1997) 10:1552–1558.
   PubMed Web of Science ®Google Scholar
• BALDUCCI L: Geriatric oncology: challenges for the new century. Eur J. Cancer (2000) 36:1741–1754.
   PubMed Web of Science ®Google Scholar
• TURNER N, SCARPACE PJ, LOWENTAL DT: Geriatric pharmacology: basic and clinical considerations. Ann. Rev Pharmacol Toxicol (1992) 32:271–302.
   PubMed Web of Science ®Google Scholar
• MAYERSOHN M: Pharmacokinetics in the elderly. Environ. Health Perspect. (1994) 102\(Suppl. 11):119–124.
   Google Scholar
• LITCHMAN SM, VILLANI G: Chemotherapy in the elderly: pharmacologic considerations. Cancer Control (2000) 7:548–556.
   PubMedGoogle Scholar
• BALDUCCI L, STANTA G: Cancer in the frail patients: a coming epidemic. Hematol. Oncol North. Am. (2000) 14:235–250.
   PubMed Web of Science ®Google Scholar
• BALDUCCI L, EXTERMANN M: Management of the frail person with advanced cancer. Crit. Rev. Oncol Hematol (2000) 33:143–148.
   PubMed Web of Science ®Google Scholar
• EVANS WK: Controversies in the management of elderly patients with small-cell lung cancer. America] Socieg, of Clinical Oncolology, 1997 Educational Book, 33rd Annual Meeting, May 17–20 1997, Denver (CO), pp. 376–381.
   Google Scholar
• GOODWIN JS, HUNT WC, HUMBLE CG, KEY CR, SAMET JM: Cancer treatment protocols: who gets chosen. Arch. Intern. Med. (1988) 148:2258–2260.
   PubMed Web of Science ®Google Scholar
• SAMET J, HUNT WC, KEY C, HUMBLE CG, GOODWIN JS: Choice of cancer therapy varies with age of patient. JAMA (1986) 225:3385–3390.
   Google Scholar
• GREENBERG ER, CHUTE CG, STUKEL T et al: Social economic factors in the choice of lung cancer treatment. A population-based study in two rural states. N. Engl. J. Med. (1988) 318:612–617.
   PubMed Web of Science ®Google Scholar
• HUTCHINS LF, UNGER JM, CROWLEY JJ, COLTMAN CA JR, ALBAIN KS: Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl. J. Med. (1999) 341:2061–2067.
   PubMed Web of Science ®Google Scholar
• FENTIMAN IS, TIRELLI V, MONFARDINI S et al: Cancer in the elderly: why so badly treated? Lancet (1990) 28:1020–1022.
   Web of Science ®Google Scholar
• DIXON DO, NEILAN B, JONES SE et al.: Effect of age on therapeutic outcome in advanced diffuse hystiocytic lymphoma: the Southwest Oncology Group experience. Clin. Oncol (1986) 4:295–305.
   Web of Science ®Google Scholar
• LANGER CJ, MANOLA J, BERNARDO P et al: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J. Natl. Cancer Inst. (2002) 94:173–181.
   PubMed Web of Science ®Google Scholar
• ROWE JM, ANDERSEN JW, MAZZA JJ et al: A randomized placebo-controlled Phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenus leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood (1995) 86:457–462.
   PubMed Web of Science ®Google Scholar
• SARGENT DJ, GOLDBERG RM, JACOBSON SD et al: A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl. J. Med. (2001) 345:1091–1097.
   PubMed Web of Science ®Google Scholar
• YANCIK R, GANZ P, VARRICCHIO CG, CONLEY B: Perspective on comorbidities and cancer in older patients: approaches to expand the knowledge base. J. Clin. Oncol (2001) 19:1147–1151.
   PubMed Web of Science ®Google Scholar
• BALDUCCI L, EXTERMANN M, CARRECA I: Management of breast cancer in the older woman. Cancer Control (2001) 8:431–441.
   PubMedGoogle Scholar
• FRIED LP, TANGEN CM, WALSTON J et al.: Frailty in older adults: evidence for a phenotype. J. Cerontol A. Biol. Sri. Med. ScL (2001) 56:M146–M156.
   Web of Science ®Google Scholar
• SALIBA D, ELLIOTT M, RUBENSTEIN LZ et al: The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J. Am. Ceriatr. Soc. (2001) 49:1691–1699.
   Web of Science ®Google Scholar
• PERRONE F, GRIDELLI C, CIGOLARI S et al: Baseline assessment of quality of life (QoL) is a strong prognostic factor for survival of elderly patients with advanced non-small cell lung cancer (NSCLC). A secondary analysis of the MILES study. Proceedings of the 38th American Society of Clinical Oncology, Orlando, USA (2002) (abstract 1346) 21:337a.
   Google Scholar
• GANZ PA, LEE JJ, SIAU J: Quality of lifeassessment. An independent prognostic variable for survival in lung cancer. Cancer (1991) 67:3131–3135.
   Google Scholar
• MONFARDINI S: Prescribing anti-cancer drugs in elderly cancer patients. Ern: Cancer (2002) 38:2341–2346.
   PubMed Web of Science ®Google Scholar
• BERNARD SA, BRUERA E: Drug interactions in palliative care. Clin. Oncol (2000) 18:1780–1799.
   Web of Science ®Google Scholar
• KALASH GR: Psychotropic drug metabolism in the cancer patient: clinical aspects of management of potential drug interactions. Psychooncology (1998) 7:307–320.
   PubMed Web of Science ®Google Scholar
• BALDUCCI L, HARDY CL, LYMAN GH: Hemopoietic reserve in the older cancer patients: clinical and economic considerations. Cancer Control (2000) 7:539–547.
   PubMedGoogle Scholar
• BALDUCCI L: Guidelines for the management of older cancer patients. Cancer Treat. Res. (2005) 124:233–256.
   PubMedGoogle Scholar
• ••Benchmark guidelines for the managementof elderly cancer patients.
   Google Scholar
• OZER H, ARMITAGE JO, BENNET CL et al: 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. Clin. Oncol (2000) 18:3558–3585.
   Google Scholar
• ••Benchmark guidelines for the clinicalpractice use of colony-stimulating growth factors.
   Google Scholar
• SCHRIJVERS D, HIGHLEY M, DE BRUYN E, VAN OOSTEROM AT, VERMORKEN JB: Role of red blood cells in pharmacokinetics of chemotherapy agents. Anticancer Drugs (1999) 10:147–153.
   PubMed Web of Science ®Google Scholar
• RIZZO JD, LICHTIN AE, WOOLF SH et al: Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood (2002) 100:2303–2320.
   PubMed Web of Science ®Google Scholar
• ••Benchmark guidelines for the clinicalpractice use of epoetin.
   Google Scholar
• BALDUCCI L, EXTERMANN M: Cancer and aging. An evolving panorama. Hematol Oncol Clin. North. Am. (2000) 14:1–16.
   PubMed Web of Science ®Google Scholar
• CRIVELLARI D, BONETTI M, CASTIGLIONE-GERTSCH M et al: Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J. Clin. Oncol (2000) 18:1412–1422.
   PubMed Web of Science ®Google Scholar
• REPETTO L: Greater risks of chemotherapy toxicity in elderly patients with cancer. .J. Support. Oncol (2003) l\(Suppl. 2):18–24.
   Google Scholar
• CVITKOVIC E, SPAULDING J, BETHUNE V, MARTIN J, WHITMORE W: Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer (1977) 39:1357–1361.
   PubMed Web of Science ®Google Scholar
• HAYES D, CVITKOVIC E, GOLBEY R, SCHEINER E, HELSON 1, KRAKOFF IH: High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer (1977) 39:1372–1381.
   PubMed Web of Science ®Google Scholar
• O'DWYER P, STEVENSON J, JOHNSON S: Clinical status of cisplatin, carboplatin and other platinum-based antitumor drugs. In: Cisplatin: chemistry and biochemistry of a lea ding Anti-Cancer drug. Lippert B (Ed.), Verlag Helvetica Chimica Acta, Zurich (1999):31–47.
   Google Scholar
• JOHNSON SW, STEVENSON JP, O'DWYER PJ: Cisplatin and its analogues. In: Cancer principles and practice of oncology. DeVita VT, Jr., Hellman S, Rosenberg SA (6th Ed.), Lippincot Williams and Wilkins, Philadelphia (2001):376–388.
   Google Scholar
• •Detailed discussion of platinum compounds.
   Google Scholar
• DESOIZE B, MADOULET C: Particular aspects of platinum compounds used at present in cancer treatment. nit. Rev Oncol Hematol (2002) 42:317–325.
   PubMed Web of Science ®Google Scholar
• •Good summary of main platinum compounds used in clinical practice: cisplatin, carboplatin, oxaliplatin and nedaplatin.
   Google Scholar
• HUBBARD K, PAZDUR R, AJANI J et al.: Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. Am. J. Clin. Oncol (1992) 15:524–527.
   PubMed Web of Science ®Google Scholar
• MURPHY D, LIND M, PRENDIVILLE J et al.: Phase I/II study of intraperitoneal iproplatin in patients with minimal residual disease following platinum-based systemic therapy for epithelial ovarian carcinoma. Eur. J. Cancer (1992) 28A:870–872.
   PubMed Web of Science ®Google Scholar
• SCHILDER R, LACRETA F, PEREZ R et al.: Phase I and pharmacokinetic study of ormaplatin (tetraplatin NSC 363812) administered on a day 1 and day 8 schedule. Cancer Res. (1994) 54:709–717.
   PubMed Web of Science ®Google Scholar
• KELLAND L: The development of orally active platinum drugs. In: Cisplatin: chemistry and biochemistry of a leading Anti-Cancer drug. Lippert B (Ed.), Verlag Helvetica Chimica Acta, Zurich (1999):497–512.
   Google Scholar
• FOKKEMA E, GROEN HJ, BAUER J, UGES DR, WEIL C, SMITH IE: Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. J. Clin. Oncol (1999) 17:3822–3827.
   PubMed Web of Science ®Google Scholar
• JUDSON I, CERNY T, EPELBAUM R et al: Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation. Ann. Oncol (1997) 8:604–606.
   PubMed Web of Science ®Google Scholar
• MANZOTTI C, PRATESI G, MENTA E et al: BBR3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin. Clin. Cancer Res. (2000) 6:2626–2634.
   PubMed Web of Science ®Google Scholar
• GOURLEY C, CASSIDY J, EDWARDS C et al: A Phase I study of the trinuclear platinum compound, BBR3464, In combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer. Cancer Chemother. Pharmacol (2004) 53:95–101.
   PubMed Web of Science ®Google Scholar
• TRIGO J, BEALE P, JUDSON I et al.: Phase I and pharmacokinetic (PK) study of cis-amminedichloro (2-methylpyridine) platinum (II) (ZD0473), a novel sterically hindered platinum complex, in patients (pts) with advanced solid malignancies. Proceedings of the 35th American Society of Clinical Oncology, Atlanta, USA (1999) (abstract 648) 18:169a.
   Google Scholar
• GELMON KA, VANDENBERG TA, PANASCI L et al.: A Phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group trial, IND 129. Ann. Oncol (2003) 14:543–548.
   PubMed Web of Science ®Google Scholar
• FLAHERTY KT, STEVENSON JP, REDLINGER M, ALGAZY KM, GIATONIO B, D'WYER PJ: A Phase I, dose escalation of ZD0473, a novel platinum analogue, in combination with gemcitabine. Cancer Chemother. Pharmacol (2004) 53:404–408.
   PubMed Web of Science ®Google Scholar
• TREAT J, SCHILLER J, QUOIX E et al:ZD0473 treatment in lung cancer: an overview of the clinical trial results. Eur. J. Cancer (2002) 38 (Suppl. 8):513–518.
   Google Scholar
• PEREZ-SOLER R, KHOKHAR AR, LOPEZ-BERESTEIN G: Treatment and prophylaxis of experimental liver metastases of M5076 reticulosarcoma with cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum encapsulated in multilamellar vesicles. Cancer Res. (1987) 47:6462–6466.
   PubMed Web of Science ®Google Scholar
• PEREZ-SOLER R, FRANCIS K, AL-BAKERS, PILKIEWICZ F, KHOKHAR AR: Preparation and characterization of liposomes containing a lipophilic cisplatin derivative for clinical use. J. Microencapsul (1994) 11:41–54.
   PubMed Web of Science ®Google Scholar
• PEREZ-SOLER R, YANG LY, DREWINKO B, LAUTERZSTAIN J, KHOKHAR AR: Increased cytotoxicity and reversal of resistance to cis-diamminedichloro-platinum(II) with entrapment of cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II) in mulitilamellar lipid vesicles. Cancer Res. (1988) 48:4509–4512.
   PubMed Web of Science ®Google Scholar
• PEREZ-SOLER R, LOPEZ-BARESTEIN G, LAUTERSZTAIN J et al: Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexaneplatinum (II). Cancer Res. (1990) 50:4254–4259.
   PubMed Web of Science ®Google Scholar
• ANONYMOUS: Chemotherapy for non-small cell lung cancer: Non-small Cell Lung Cancer Collaborative Group. Cochrane Database Syst. Rev (2000) CD002139.
   Google Scholar
• CULLEN MH, BILLINGHAM LJ, WOODROFFE CM et al: Mitomycin, ifosfamide and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life. J. Clin. Oncol (1999) 17:3188–3194.
   PubMed Web of Science ®Google Scholar
• THONGPRASERT S, SANGUANMITRA P, JUTHAPAN W, CLINCH J: Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: Best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer (1999) 24:17–24.
   PubMed Web of Science ®Google Scholar
• SPIRO SG, RUDD RIVI, SOUHAMI RL et al.: Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax (2004) 59:828–836.
   PubMed Web of Science ®Google Scholar
• CRINO L, SCAGLIOTTI GV, RICCI S et al.: Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized Phase III study of the Italian Lung Cancer Project. I Clin. Oncol (1999) 17:3522–3530.
   PubMed Web of Science ®Google Scholar
• GEBBIA V, GALETTA D, RICCARDI R et al.: Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized study. Lung Cancer (2002) 37:179–187.
   PubMed Web of Science ®Google Scholar
• GIACCONE G, SPLINTER TA, DEBRUYNE C et al.: Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer: The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Clin. Oncol (1998) 16:2133–2141.
   Web of Science ®Google Scholar
• LE CHEVALIER T, BRISGAND D, DOUILLARD JY et al: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of European multicenter trial including 612 patients.J. Clin. Oncol (1994) 12:360–367.
   PubMed Web of Science ®Google Scholar
• CARDENAL F, LOPEZ-CABRERIZO MP, ANTON A et al: Randomized Phase III study of gemcitabine -cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol (1999) 17:12–18.
   PubMed Web of Science ®Google Scholar
• BONOMI P, KIM K, FAIRCLOUGH D et al: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial. Clin. Oncol (2000) 18:623–631.
   Web of Science ®Google Scholar
• HOTTA K, MATSUO K, UEOKA H, KIURA K, TABATA M, TANIMOTO M: Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small cell lung cancer. J. Clin. Oncol (2004) 22:3852–3859.
   PubMed Web of Science ®Google Scholar
• ••Detailed meta-analysis of randomisedPhase III trials containing cisplatin-or carboplatin-based regimens.
   Google Scholar
• CHAN AM, MAO AJ, WU T et al: Meta-analysis comparing carboplatin and cisplatin-based chemotherapy in advanced non-small cell lung cancer. J. Clin. Oncol (2005) 23(16S):674s (abstract 7218).
   Google Scholar
• LE CHEVALIER T, SCAGLIOTTI G, NATALE R et al: Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non small cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer (2004) 47:69–80.
   Web of Science ®Google Scholar
• PFISTER DG, JOHNSON DH, AZZOLI CG et al: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J. Clin. Oncol (2004) 22:330–353.
   PubMed Web of Science ®Google Scholar
• ••Benchmark guidelines for the treatmentof advanced NSCLC.
   Google Scholar
• EARLE CC, TSAI JS, GELBER RD, WEINSTEIN MC, NEUMANN PJ, WEEKS JC: Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J. Clin. Oncol (2001) 19:1064–1070.
   PubMed Web of Science ®Google Scholar
• ELDERLY LUNG CANCER VINORELBINE ITALIAN STUDY (ELVIS) GROUP: Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. Natl. Cancer Inst. (1999) 91:66–72.
   Google Scholar
• •A key randomised Phase III trial ever performed in advanced NSCLC elderly patients.
   Google Scholar
• FRASCI G, LORUSSO V, PANZA N et al: Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. Oncol (2000) 18:2529–2536.
   Google Scholar
• GRIDELLI C, PERRONE F, GALLO C et al.: Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III randomized trial. J. Natl. Cancer Inst. (2003) 95:362–372.
   PubMed Web of Science ®Google Scholar
• •The largest randomised Phase III trial ever performed in advanced NSCLC elderly patients.
   Google Scholar
• DEPIERRE A, CHASTANG Cl, QUOIX E et al: Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann. OncoL (1994) 5:37–42.
   PubMed Web of Science ®Google Scholar
• CRAWFORD J, O'ROURKE M, SCHILLER JH et al.: Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J. Clin. OncoL (1996) 14:2774–2784.
   Google Scholar
• GRIDELLI C, AAPRO M, ARDIZZONI A et al.: Treatment of advanced non-small-cell lung cancer in the elderly: results of an international expert panel. J. Clin. OncoL (2005) 23:3125–3137.
   PubMed Web of Science ®Google Scholar
• ••Benchmark guidelines for the treatmentof advanced NSCLC elderly patients.
   Google Scholar
• TAKEDA K, KUDOH S, NAKAGAWA K et al.: Randomized Phase III study of docetaxel (D) versus vinorelbine (V) for elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): Results of a West Japan Thoracic Oncology Group trial (WJTOG9904).OncoL(2005) 23(165):623s (abstract 7009).
   Google Scholar
• •First randomised Phase III trial comparing two single-agent in the treatment of advanced non-small cell lung cancer elderly patients.
   Google Scholar
• OSHITA F, KURATA T, KASAI et al: Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions. fpn. J. Cancer Res. (1995) 86:1198–1202.
   PubMedGoogle Scholar
• RINALDI M, DE MARINIS F, ARDIZZONI A et al: Correlation between age and prognosis in patients with advanced non small cell lung cancer treated with cisplatin containing chemotherapy: a retrospective multicentre study. Ann. Oncol (1994) 5\(Suppl. 8):58.
   Google Scholar
• KUBOTA K, HOSOMURA K, KAKINUMA R et al.: Cisplatin nephrotoxicity in elderly patients with lung cancer. Proceedings of the 34th American Society of Clinical Oncology, Los Angeles, USA (1998) (abstract 1890) 17:491a.
   Google Scholar
• LICHTMAN SM, BUCHHOLTZ M, MARINO J et al.: Use of cisplatin for elderly patients. Age Ageing (1992) 21:202–204.
   PubMed Web of Science ®Google Scholar
• •Specific evaluation of cisplatin administration in elderly cancer patients.
   Google Scholar
• THYSS A, SAUDES L, OTTO J et al: Renal tolerance of cisplatin in patients more than 80 years old.J. Clin. OncoL (1994) 12:2121–2125.
   PubMed Web of Science ®Google Scholar
• •Specific evaluation of cisplatin administration in elderly cancer patients.
   Google Scholar
• CUBILLO A, CORNIDE M, LOPEZ JL eta].: Renal tolerance to cisplatin in patients 70 years and older. Am. J. Clin. OncoL (2001) 24:192–197.
   Google Scholar
• •Specific evaluation of cisplatin administration in elderly cancer patients.
   Google Scholar
• NGUYEN B, SANDLER A, DENHAM C: The safety and efficacy of gemcitabine plus cisplatin in the elderly chemo-naive NSCLC patients (age 70 years) as compared to those with age 70 years. Proceedings of the 35th American Society of Clinical Oncology, Atlanta, USA (1999) (abstract 1818) 18:471a.
   Google Scholar
• KELLY K, GIARRITTA S, AKERLEY W et al: Should older patient (pts) receive combination chemotherapy for advanced stage non-small cell lung cancer (NSCLC)? An analysis of Southwest Oncology Trials 9509 and 9308. Proceedings of the 37th American Society of Clinical Oncology, San Francisco, USA (2001) (abstract 1313) 20:329a.
   Google Scholar
• LILENBAUM RC, HERNDON J 2nd, LIST MA et al: Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: the cancer and leukemia group B (study 9730). J. Clia Oncol (2005) 23:190–196.
   PubMed Web of Science ®Google Scholar
• ROCHA LIMA CM, HERNDON JE 2nd, KOSTY M, CLAMON G, GREEN MR: Therapy choices among older patients with lung carcinoma. Cancer (2002) 94:181–187.
   PubMed Web of Science ®Google Scholar
• LANGER CJ, VANGEL J, SCHILLER DP et al: Age-specific subanalysis of ECOG 1594: fit elderly patients (70–80 yrs) with NSCLC do as well as younger patients (70). Proceedings of the 39th American SocitV of Clinical Oncology, Chicago, USA (2003) (abstract 2571) 22:639.
   Google Scholar
• FOSSELLA FV, BELANI CP: Phase II study (TAX 326) of docetaxel-cisplatin (DC) and docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) for the first-line treatment of advanced/metastatic non-small-cell-lung cancer (NSCLC): analysis in elderly patients. Proceedings of the 39th American Society of Clinical Oncology, Chicago, USA (2003) 22:629 (abstract 2528).
   Google Scholar
• HENSING TA, PETERMAN AH, SCHELL MJ, LEE JH, SOCINSKI MA: The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer (2003) 98:779–88.
   PubMed Web of Science ®Google Scholar
• BELANI C, RAMALINGAM S, PERRY MC et al: Phase III randomized trial comparing weekly versus standard schedules of paclitaxel (P) plus carboplatin (C) for advanced non-small cell lung cancer (NSCLC): Analyses of elderly patients. Lung Cancer (2005) 49\(Suppl. 2):532 (abstract 0–088).
   Google Scholar
• SCHILLER JH, HARRINGTON D, BELANI CP et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl. J. Med. (2002) 346:92–98.
   PubMed Web of Science ®Google Scholar
• FOSSELLA F, PEREIRA JR, VON PAWEL J et al.: Randomized, multinational, Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study." Clin. Oncol (2003) 21:3016–3024.
   Google Scholar
• OSHITA F, KURATA T, KASAI T et al: Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ function. fpn. Cancer Res. (1995) 86:1198–1202.
   Web of Science ®Google Scholar
• SOUQUET PJ, BOMBARON P, BRUNEL-CROVA J et al.: Treatment of advanced and disseminated non small cell lung cancer (NSCLC) in elderly patients: results of MIC regimen. Lung Cancer (1997) 18\(Suppl. 1):24.
   Google Scholar
• MATTIOLI R, MORESE R, IMPERATORI L et al: Weekly cisplatin (P) and vinorelbine (V) is active, manageable and provides clinical benefit in advanced non-small cell lung cancer (ANSCLC) elderly or poor performance status (PS) patients. Ann. Oncol (2002) 13\(Suppl. 5):104 (abstract 377P).
   Google Scholar
• PEREIRA JR, MARTINS SJ, NIKAEDO SM, MARI FK: Chemotherapy with cisplatin and vinorelbine for elderly patients with locally advanced or metastatic non-small-cell lung cancer. B.MC. Cancer (2004) 29:69–73.
   Web of Science ®Google Scholar
• LIPPE P, SILVA RR, GIULIODORI L et al: Advanced non-small cell lung cancer in the elderly: effective and well tolerated weekly gemcitabine and cisplatin regimen. A pilot study. Minerva Med. (2000) 91:53–57.
   PubMedGoogle Scholar
• MOSCETTI L, SALTARELLI R, SIGNORELLI C et al: The combination of gemcitabine (G) and cisplatin (P) in the general population of elderly patients with advanced NSCLC. Lung Cancer (2003) 42\(Suppl. 2):596 (abstract P23).
   Google Scholar
• BERARDI R, PORFIRI E, SCARTOZZI M et al: Elderly patients with advanced non-small cell lung cancer. A Phase II study with weekly cisplatin and gemcitabine. Oncology (2003) 65:198–203.
   Google Scholar
• FELIU J, MARTIN G, MADRONAL C et al: Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non-small cell lung cancer. Cancer Chemother. Pharmacol (2003) 52:247–252.
   PubMed Web of Science ®Google Scholar
• OHE Y, NIHO S, KAKINUMA R et al: A Phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. Ann. Oncol (2004) 15:45–50.
   PubMed Web of Science ®Google Scholar
• VAN DEN BRANDE, KEYSER EM, SELLESLAG D, DEMEDTS M: Serious myelotoxicity of a carboplatin-etoposide regimen for advanced non small cell lung cancer. Lung Cancer (1991) 7:317–321.
   Google Scholar
• ROSTI G, ZUMAGLINI F, GRIDELLI C et al: Carboplatin and oral VP-16 in advanced lung cancer patients aged 70 years. A Phase II trial. Proceedings of 2nd International Conference on Cancer in the Elderly, Genova, Italy (1994) p. 225.
   Google Scholar
• THOMAS P, CASTELNAN O, KLEISSSBAUER JP: Carboplatin plus oral etoposide in elderly patients with bronchogenic carcinoma. Preliminary results of a Phase II trial. Proceedings of 2nd International Conference on Cancer in the Elderly, Genova, Italy (1994) p. 226.
   Google Scholar
• SHIBATA K, NAKATSUMI Y, KASAHARA K, BANDO T, FUJIMURA M, MATSUDA T: Analysis of thrombocytopenia due to carboplatin combined with etoposide in elderly patients with lung cancer." Cancer Res. Clin. Oncol (1996) 122:437–442.
   PubMed Web of Science ®Google Scholar
• GRIDELLI C, ROSSI A, SCOGNAMIGLIO F et al: Carboplatin plus oral etoposide in elderly patients with advanced non small cell lung cancer. A Phase II study. Anti-Cancer Res. (1998) 17:4755–4758.
   Web of Science ®Google Scholar
• IMPERATORI L, MATTIOLI R, CASADEI V et al.: Weekly carboplatin + fluorouracil + folinic acid in advanced NSCLC of the elderly: efficacy in symptoms relief. Proceedings of 8th International Congress on Anti-Cancer Treatment, Paris, France (1998) p. 203 (abstract P268).
   Google Scholar
• COLLEONI M, VICARIO G, PANCHERI F et al: Weekly carboplatin and vinorelbine in elderly patients with non-small-cell lung cancer (NSCLC). Proceedings 6th International Congress on Anti-Cancer Treatment, Paris, France (1996) p. 194 (abstract 562).
   Google Scholar
• SANTOMAGGIO CR, TUCCI E: Chemoterapia con carboplatino (CBDCA) e vinorelbina (V) nell'anziano affetto da carcinoma polmonare con microcitoma, stad avanzati (A-NSCLC). Chemother. (1996) 8(Suppl. 3):104.
   Google Scholar
• MAESTU I, GOMEZ-ALDARAVI L, TORREGROSA MD et al: Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer. Lung Cancer (2003) 42:345–354.
   PubMed Web of Science ®Google Scholar
• MASTERS GA, NICKOLOV A, HAHN E, HELEN F: Gemcitabine (GEM) and carboplatin (CARB) in elderly patients with advanced non-small cell lung cancer (NSCLC): Subset analysis of a randomized Phase II trial. J. Clin. Oncol. (2005) 23(165):679s (abstract 7236).
   Google Scholar
• MOLINIER O, MILLERON B, BRETON JL et al.: Multicenter Phase II trial of carboplatin and weekly paclitaxel as first-line treatment in elderly patients with non-small cell lung cancer: preliminary results. Proceedings of the 39th American Socieg, of Clinical Oncology, Chicago, USA (2003) 22:693 (abstract 2786).
   Google Scholar
• JATOI A, STELLA PJ, HILLMAN S et al.: Weekly carbopatin and paclitaxel in elderly non-small-cell lung cancer patients (> or = 65 years of age): a Phase II North Central Cancer Treatment Group study. Am. J. Clin. Oncol. (2003) 26:441–447.
   PubMed Web of Science ®Google Scholar
• CHOI IS, KIM BS, PARK SR et al.: Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer. Lung Cancer (2003) 39:99–101.
   PubMed Web of Science ®Google Scholar
• OKAMOTO I, MORIYAMA E, FUJII S et al.: Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer. fpn.Oncol. (2005) 35:188–194.
   Web of Science ®Google Scholar
• USUI K, INOUE A, ISHIMOTO 0 et al.: A Phase II trial of weekly paclitaxel and carboplatin for elderly patients with advanced non-small cell lung cancer (NSCLC).Oncol. 23(165):682s(abstract 7248).
   Google Scholar
• MARSLAND TA, GARFIELD DH, KHAN MM, LOOK RM, BOEHM KA, ASMAR L: Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials. Lung Cancer (2005) 47:111–120.
   PubMed Web of Science ®Google Scholar
• BUOSI R, POLETTI S; CANTELE V et al.: preliminary results of Phase II trial with combination of gemcitabine and oxaliplatin in elderly patients with advanced NSCLC. Proceedings of the 39th American Socieg, of Clinical Oncology, New Orleans, USA (2004) (abstract 7348) 23:700.
   Google Scholar
• DOMENECH M, LOSA F, BLANCO R et al.: Phase II study of gemcitabine plus oxaliplatin as first-line treatment in elderly or unfit patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer (2005) 49\(Suppl. 2):S242 (abstract P476).
   Google Scholar
• OSHITA F, YAMADA K, SAITO H, NODA K, HAMANAKA M, IKEHARA M: Phase II study of nedaplatin and irinotecan for elderly patients with advanced non-small cell lung cancer. Exp. Thar. Oncol. (2004) 4:343–348.
   PubMedGoogle Scholar
• SILVESTRI G, PRITCHARD R, WELCH HG: Preferences for chemotherapy in patients with advanced non-small-cell lung cancer: descriptive study based on scripted interviews. Br. Med. J. (1998) 317:771–775.
   PubMed Web of Science ®Google Scholar
• PERRONE F, GALLO C, GRIDELLI C: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J. Nati Cancer Inst. (2002) 94:1029–1030.
   PubMed Web of Science ®Google Scholar
• KLASTERSKY J, SCULIER JP, RAVEZ P et al: A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide and NSCLC. Clin. Oncol. (1986) 4:1780–1786.
   Web of Science ®Google Scholar
• GANDARA DR, CROWLEY J, LIVINGSTON RB et al.: Evaluation of cisplatin intensity in metastatic NSCLC: a Phase III study of the SWOG. Clin. Oncol. (1993) 11:873–878.
   Web of Science ®Google Scholar
• EINHORN L: Carboplatin versus cisplatin in lung cancer. Lung Cancer (2005) 49\(Suppl. 3):532–535.
   Google Scholar
• MINAMI H, OHE Y, NIHO S et al: Comparison of pharmacokinetics and pharmacodynamics of docetaxel and cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients? Clin. Oncol. (2004) 22:2901–2908.
   Google Scholar